Revenue (Quarterly) Chart

Historical Revenue (Quarterly) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 0.0439M
March 31, 2026 0.051M
December 31, 2025 0.1623M
September 30, 2025 0.1289M
June 30, 2025 0.1522M
March 31, 2025 0.2493M
December 31, 2024 0.1181M
September 30, 2024 0.2278M
June 30, 2024 3.196M
March 31, 2024 0.0674M
December 31, 2023 0.0473M
September 30, 2023 0.0484M
June 30, 2023 0.7271M
March 31, 2023 0.0529M
December 31, 2022 0.4243M
September 30, 2022 0.0578M
June 30, 2022 0.0847M
March 31, 2022 0.0946M
December 31, 2021 0.0967M
September 30, 2021 0.0999M
June 30, 2021 0.0914M
March 31, 2021 0.0848M
December 31, 2020 0.0574M
Date Value
September 30, 2020 0.066M
June 30, 2020 0.0651M
March 31, 2020 0.0642M
December 31, 2019 0.0644M
September 30, 2019 0.0652M
June 30, 2019 -0.3093M
March 31, 2019 0.9896M
December 31, 2018 0.00
September 30, 2018 0.00
June 30, 2018 0.00
March 31, 2018 0.00
December 31, 2017 0.00
September 30, 2017 0.00
June 30, 2017 0.0603M
March 31, 2017 0.1846M
December 31, 2016 0.182M
September 30, 2016 0.1548M
June 30, 2016 0.1965M
March 31, 2016 0.1794M
December 31, 2015 0.1798M
September 30, 2015 0.1408M
June 30, 2015 0.3232M
March 31, 2015 0.1668M

Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (Quarterly) Range, Past 5 Years

View Revenue (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue (Quarterly) Benchmarks

View Revenue (Quarterly) Benchmarks
Start Trial
3-D Matrix Ltd. 20.10M
GNI Group Ltd. 40.23M
AnGes, Inc. 1.876M
ACADIA Pharmaceuticals, Inc. 307.96M
Alkermes Plc 496.01M